Flagship Biosciences offers two hour training course in advanced topics in digital pathology. These courses are held once weekly, with enough time between courses for students to practice what is learned in the previous course. Flagship Biosciences provides histopathology services to biotech,pharmaceutical, medical device and cosmetics companies.
They deliver their pathology services digitally, providing accurate measurements of efficacy and toxicity across an entire tissue section.
They also recently named Dr. Steven Potts formerly of Aperio as their new CEO and Chairman. Bio below from Flagship Biosciences website.
Steven J. Potts, Ph.D., MBA. CEO and Chairman
Dr. Potts joined Flagship from Aperio, where he was Vice President of Life Sciences. He managed worldwide sales and marketing in the biopharma segment, where his team achieved global adoption by nearly all of the largest pharmaceutical companies. He defined and led the GLP product development and validation services for the use of whole slide images in regulated preclinical and clinical trials studies, as well as the development of image analysis techniques for angiogenesis. Prior to Aperio, he was Head of Bioinformatics and Biostatistics at Quest Diagnostics Nichols Institute, where his team supported the development of In Vitro Diagnostics Multianalyte Assays (IVDMIA) in oncology and other therapeutic areas. He was a product manager at Accelrys, where he created a protein-ligand data management system for medicinal and computational chemists, crystallographers, and biologists to provide structural bioinformatics data across multiple pharmaceutical departments. He earned a Ph.D. and M.S. in Biological Engineering, and an MBA from the University of California at Davis, and a B.S. in Physics from Wheaton College, Illinois. He has over 20 peer-reviewed publications and patents.